• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia.

作者信息

Kong Jinyu, Chen Nan, Li Mengyun, Zhang Jian, Wu Xiaoxia, Zong Lihong, Wu Depei, Song Baoquan, Qiu Huiying

机构信息

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.

Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.

出版信息

Ann Hematol. 2022 Mar;101(3):697-699. doi: 10.1007/s00277-021-04530-y. Epub 2021 May 6.

DOI:10.1007/s00277-021-04530-y
PMID:33954816
Abstract
摘要

相似文献

1
Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia.维奈托克与地西他滨治疗难治性TP53突变的早期T细胞前体急性淋巴细胞白血病
Ann Hematol. 2022 Mar;101(3):697-699. doi: 10.1007/s00277-021-04530-y. Epub 2021 May 6.
2
Venetoclax combined with decitabine and HAAG regimen: a novel salvage strategy for relapsed/refractory T-cell acute lymphoblastic leukaemia.维奈托克联合地西他滨及HAAG方案：复发/难治性T细胞急性淋巴细胞白血病的一种新型挽救策略
Ann Hematol. 2022 Nov;101(11):2525-2528. doi: 10.1007/s00277-022-04912-w. Epub 2022 Sep 5.
3
Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma.维奈托克与地西他滨治疗儿童难治性T细胞淋巴母细胞淋巴瘤
J Pediatr Hematol Oncol. 2021 Oct 1;43(7):e991-e996. doi: 10.1097/MPH.0000000000002050.
4
Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia.维奈托克联合化疗用于复发/难治性早期T细胞前体急性淋巴细胞白血病
Leuk Lymphoma. 2021 Sep;62(9):2292-2294. doi: 10.1080/10428194.2021.1897807. Epub 2021 Mar 10.
5
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab.使用地西他滨/维奈克拉和达雷妥尤单抗治疗与治疗相关的急性髓系白血病及潜在的多发性骨髓瘤。
Ann Hematol. 2021 Jun;100(6):1637-1640. doi: 10.1007/s00277-021-04490-3. Epub 2021 Mar 13.
6
Low-dose venetoclax, bortezomib, inotuzumab, rituximab, and dexamethasone (LoVe-BIRD) in a child with relapsed/refractory B-cell acute lymphoblastic leukemia with TP53 mutation.低剂量维奈克拉、硼替佐米、伊奈妥单抗、利妥昔单抗和地塞米松（LoVe-BIRD方案）用于一名复发/难治性伴有TP53突变的B细胞急性淋巴细胞白血病儿童。
Pediatr Blood Cancer. 2024 Sep;71(9):e31152. doi: 10.1002/pbc.31152. Epub 2024 Jul 2.
7
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.维奈克拉、FLT3抑制剂和地西他滨三联疗法治疗FLT3突变的急性髓系白血病。
Blood Cancer J. 2021 Feb 1;11(2):25. doi: 10.1038/s41408-021-00410-w.
8
Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia.维奈托克联合波纳替尼治疗T315I/复合突变的Ph+急性淋巴细胞白血病
Blood Cancer J. 2022 Jan 28;12(1):20. doi: 10.1038/s41408-022-00621-9.
9
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.10天阿扎胞苷联合维奈克拉用于新诊断的不适合强化化疗以及复发或难治性急性髓系白血病的治疗：一项单中心2期试验
Lancet Haematol. 2020 Oct;7(10):e724-e736. doi: 10.1016/S2352-3026(20)30210-6. Epub 2020 Sep 5.
10
Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen.维奈克拉联合HAG方案挽救了复发/难治性早期T细胞前体急性淋巴细胞白血病。
Ann Hematol. 2020 Feb;99(2):395-397. doi: 10.1007/s00277-019-03902-9. Epub 2019 Dec 26.

引用本文的文献

1
Combination of venetoclax with CHG regimen in refractory/relapsed T-lymphoblastic lymphoma/acute lymphoblastic leukemia: a case series and literature review.维奈托克与CHG方案联合治疗难治性/复发性T淋巴细胞淋巴瘤/急性淋巴细胞白血病：病例系列及文献综述
Discov Oncol. 2025 Jul 1;16(1):1202. doi: 10.1007/s12672-025-03055-4.
2
Venetoclax-based low-intensity chemotherapy in the salvage treatment of relapsed/refractory T-cell acute lymphoblastic leukemia.基于维奈托克的低强度化疗用于复发/难治性T细胞急性淋巴细胞白血病的挽救治疗
Clin Exp Med. 2025 Apr 2;25(1):104. doi: 10.1007/s10238-025-01638-7.
3
Venetoclax and azacitidine in combination with homoharringtonine, cytarabine, and aclarubicin for salvage therapy of relapsed/refractory T cell acute lymphoblastic leukemia.
维奈托克与阿扎胞苷联合高三尖杉酯碱、阿糖胞苷和阿柔比星用于复发/难治性T细胞急性淋巴细胞白血病的挽救治疗。
Int J Hematol. 2025 Apr;121(4):547-552. doi: 10.1007/s12185-025-03915-3. Epub 2025 Jan 23.
4
Venetoclax for an ATRA and ATO resistance acute promyelocytic leukemia patient with fusion gene.维奈托克用于一名伴有融合基因的全反式维甲酸和三氧化二砷耐药的急性早幼粒细胞白血病患者。
Leuk Res Rep. 2024 Sep 24;22:100482. doi: 10.1016/j.lrr.2024.100482. eCollection 2024.
5
Novel Biomarkers and Molecular Targets in ALL.急性淋巴细胞白血病的新型生物标志物和分子靶点。
Curr Hematol Malig Rep. 2024 Feb;19(1):18-34. doi: 10.1007/s11899-023-00718-3. Epub 2023 Dec 4.
6
Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma.T 细胞急性淋巴细胞白血病/淋巴瘤的靶向治疗和免疫治疗。
Ann Hematol. 2023 Aug;102(8):2001-2013. doi: 10.1007/s00277-023-05286-3. Epub 2023 May 25.
7
Venetoclax Use in Paediatric Haemato-Oncology Centres in Poland: A 2022 Survey.维奈托克在波兰儿科血液肿瘤中心的应用：2022年调查
Children (Basel). 2023 Apr 19;10(4):745. doi: 10.3390/children10040745.
8
Effects of post-transplant maintenance therapy with decitabine prophylaxis on the relapse for acute lymphoblastic leukemia.地西他滨预防移植后维持治疗对急性淋巴细胞白血病复发的影响。
Bone Marrow Transplant. 2023 Jun;58(6):687-695. doi: 10.1038/s41409-023-01948-y. Epub 2023 Mar 24.
9
The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia.维奈托克为基础的治疗方案在急性淋巴细胞白血病中的新作用。
Int J Mol Sci. 2022 Sep 19;23(18):10957. doi: 10.3390/ijms231810957.
10
Targeting Apoptosis in ALL.ALL 中的细胞凋亡靶向治疗。
Curr Hematol Malig Rep. 2022 Apr;17(2):53-60. doi: 10.1007/s11899-022-00661-9. Epub 2022 May 11.